| Paul C Anderson, MD | |
|
4755 Ogeltown Stanton Road, Newark, DE 19718-0001 | |
| (302) 733-1000 | |
| (302) 733-1633 |
| Full Name | Paul C Anderson |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 38 Years |
| Location | 4755 Ogeltown Stanton Road, Newark, Delaware |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003894817 | NPI | - | NPPES |
| 0000045301 | Medicaid | DE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | C10003062 (Delaware) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christiana Hospital | Newark, DE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Christiana Care Health Services Inc | 9739097569 | 1248 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of the Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years.
Every week reporter Ankita Rao selects interesting reading from around the Web.
Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the "Outstanding Scientific Achievement" award from the Defense Threat Reduction Agency. The award was presented at the 2010 Chemical and Biological Defense Science and Technology Conference in Orlando, Florida to Dr. Justin Skoble, Associate Director, Biodefense and Process Development at Aduro BioTech.
Genetic editing has been performed in the laboratory until now. Living cells within Petri-dishes have been put under the microscope while gene editing tools such as CRISPR were used to cut, nick and replace parts of the DNA or genome that is defective with bits of DNA that is correct in its sequence. Now doctors in California have attempted to edit cells within a living person.
› Verified 8 days ago
| Entity Name | Christiana Care Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770568107 PECOS PAC ID: 9739097569 Enrollment ID: O20031201000477 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of the Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years.
Every week reporter Ankita Rao selects interesting reading from around the Web.
Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the "Outstanding Scientific Achievement" award from the Defense Threat Reduction Agency. The award was presented at the 2010 Chemical and Biological Defense Science and Technology Conference in Orlando, Florida to Dr. Justin Skoble, Associate Director, Biodefense and Process Development at Aduro BioTech.
Genetic editing has been performed in the laboratory until now. Living cells within Petri-dishes have been put under the microscope while gene editing tools such as CRISPR were used to cut, nick and replace parts of the DNA or genome that is defective with bits of DNA that is correct in its sequence. Now doctors in California have attempted to edit cells within a living person.
› Verified 8 days ago
| Entity Name | Doctors For Emergency Service |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750369674 PECOS PAC ID: 0648160341 Enrollment ID: O20040317000490 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of the Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years.
Every week reporter Ankita Rao selects interesting reading from around the Web.
Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the "Outstanding Scientific Achievement" award from the Defense Threat Reduction Agency. The award was presented at the 2010 Chemical and Biological Defense Science and Technology Conference in Orlando, Florida to Dr. Justin Skoble, Associate Director, Biodefense and Process Development at Aduro BioTech.
Genetic editing has been performed in the laboratory until now. Living cells within Petri-dishes have been put under the microscope while gene editing tools such as CRISPR were used to cut, nick and replace parts of the DNA or genome that is defective with bits of DNA that is correct in its sequence. Now doctors in California have attempted to edit cells within a living person.
› Verified 8 days ago
| Entity Name | Christiana Care Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1245674993 PECOS PAC ID: 9739097569 Enrollment ID: O20130903000474 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of the Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years.
Every week reporter Ankita Rao selects interesting reading from around the Web.
Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the "Outstanding Scientific Achievement" award from the Defense Threat Reduction Agency. The award was presented at the 2010 Chemical and Biological Defense Science and Technology Conference in Orlando, Florida to Dr. Justin Skoble, Associate Director, Biodefense and Process Development at Aduro BioTech.
Genetic editing has been performed in the laboratory until now. Living cells within Petri-dishes have been put under the microscope while gene editing tools such as CRISPR were used to cut, nick and replace parts of the DNA or genome that is defective with bits of DNA that is correct in its sequence. Now doctors in California have attempted to edit cells within a living person.
› Verified 8 days ago
| Entity Name | Christiana Care Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639956451 PECOS PAC ID: 8022468057 Enrollment ID: O20240106000968 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of the Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years.
Every week reporter Ankita Rao selects interesting reading from around the Web.
Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the "Outstanding Scientific Achievement" award from the Defense Threat Reduction Agency. The award was presented at the 2010 Chemical and Biological Defense Science and Technology Conference in Orlando, Florida to Dr. Justin Skoble, Associate Director, Biodefense and Process Development at Aduro BioTech.
Genetic editing has been performed in the laboratory until now. Living cells within Petri-dishes have been put under the microscope while gene editing tools such as CRISPR were used to cut, nick and replace parts of the DNA or genome that is defective with bits of DNA that is correct in its sequence. Now doctors in California have attempted to edit cells within a living person.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul C Anderson, MD Po Box 3048, Wilmington, DE 19804-0048 Ph: (302) 224-5878 | Paul C Anderson, MD 4755 Ogeltown Stanton Road, Newark, DE 19718-0001 Ph: (302) 733-1000 |
News Archive
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
It has long been suggested that healthy folate (the natural form of folic acid) levels in expectant mothers goes hand in hand with healthy nervous system development in their children. A study published in an upcoming issue of the Journal of Child Psychology and Psychiatry finds that low maternal folate levels is linked to the development of attention-deficit/hyperactivity problems in children at age seven to nine years.
Every week reporter Ankita Rao selects interesting reading from around the Web.
Aduro BioTech, a clinical-stage immunotherapy company, is pleased to announce the "Outstanding Scientific Achievement" award from the Defense Threat Reduction Agency. The award was presented at the 2010 Chemical and Biological Defense Science and Technology Conference in Orlando, Florida to Dr. Justin Skoble, Associate Director, Biodefense and Process Development at Aduro BioTech.
Genetic editing has been performed in the laboratory until now. Living cells within Petri-dishes have been put under the microscope while gene editing tools such as CRISPR were used to cut, nick and replace parts of the DNA or genome that is defective with bits of DNA that is correct in its sequence. Now doctors in California have attempted to edit cells within a living person.
› Verified 8 days ago
Dr. Sepehr Sedigh Haghighat, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Newark, DE 19718 Phone: 302-733-3901 | |
Valerie Ann Cohen, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Newark, DE 19718 Phone: 302-623-4050 | |
Brian E Burgess, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Road, Newark, DE 19718 Phone: 302-733-1000 Fax: 302-733-1633 | |
Kristina Louise Stransky, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Newark, DE 19718 Phone: 302-733-1042 | |
Dr. John Thomas Powell, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: Christiana Hospital Academic Affairs, Suite 2a00, Newark, DE 19718 Phone: 302-733-1557 | |
Dr. Jennifer Terrano Mink, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Christiana Hospital C/o Emergency Medicine Suite 1071, Newark, DE 19718 Phone: 302-733-1840 Fax: 302-733-1633 |